No Data
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Hong Kong stock abnormal | CRO concept stocks rebounded in the morning, overseas investment and financing gradually recovered. The pharmaceutical subdivision field and emerging businesses are expected to develop rapidly.
Concept stocks of CRO rebounded in early trading. As of the time of writing, Genscript Bio (01548) rose by 4.39% to HK$10.94; Tigermed (03347) rose by 4.47% to HK$33.85; Frontage (01521) rose by 2.75% to HK$1.12; Joinn Laboratories (06127) rose by 2.49% to HK$9.47; Wuxi Bio (02269) rose by 1.68% to HK$14.54.
Contract research organizations concept rises, Joinn Laboratories (06127) rises by 5.11%, institutions say CXO sector is expected to benefit from the recovery of overseas research and development demand.
Jinwu Financial News | The concept of contract research organizations has risen across the board, with joinn laboratories (06127) up 5.11%, tigermed (03347) up 4.33%, frontage (01521) up 2%, pharmaron (03759) up 1.84%, and wuxi bio (02269) up 0.79%. Zhongtai reported that the bank believes that as the medical insurance fund prepayment system continues to deepen and improve, and the supporting DRG/DIP system is continuously implemented in various provinces and cities, the long-term "triangle debt" relationship among hospitals, pharmaceutical companies, and medical insurance persists, and the "zero markup policy on pharmaceuticals" compresses hospital profitability.
Trending Industry Today: WUXI APPTEC Leads Losses In CRO Stocks
Frontage Holdings Corporation's (HKG:1521) P/E Is Still On The Mark Following 35% Share Price Bounce
Despite Hitting HK$1.67, Frontage Holdings Insiders Still Sold Too Soon
No Data
